Evidence map›Paper›PMID 30307652›Full record

ArticleJournal of veterinary internal medicine2018

The pharmacokinetics of gabapentin in cats.

Derek Adrian, Mark G Papich, Ronald Baynes, Emma Stafford, B Duncan X Lascelles

Open access · goldAbstract read
In one paragraph

Article in Journal of veterinary internal medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 59 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Gabapentin: Clinical Use and Pharmacokinetics in Dogs, Cats, and Horses.Animals : an open access journal from MDPI · 2023
    Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. A pilot study of transdermal gabapentin in cats.Journal of veterinary internal medicine · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Derek AdrianComparative Pain Research and Education Centre, Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, North Carolina.ORCID https://orcid.org/0000-0002-0226-6182
Mark G PapichMolecular and Biomedical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, North Carolina.ORCID https://orcid.org/0000-0002-7591-7898
Ronald BaynesPopulation Health and Pathobiology, College of Veterinary Medicine, North Carolina State University, Raleigh, North Carolina.
Emma StaffordComparative Medicine Institute, North Carolina State University, Raleigh, North Carolina.ORCID https://orcid.org/0000-0003-1092-0380
B Duncan X LascellesComparative Pain Research and Education Centre, Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, North Carolina.ORCID https://orcid.org/0000-0002-2950-9009
North Carolina State University · USUniversity of North Carolina at Chapel Hill · US

Funding

Clinical Veterinary Pharmacy Residency ProgramComparative Pain Research ProgramVeterinary Pharmacology Research Foundation, Pharmacokinetics Grant (Administered by AVMF)
6 · The paper itself

Abstract

backgroundGabapentin is the most commonly prescribed medication for the treatment of chronic musculoskeletal pain in cats. Despite this common and chronic usage, clinically relevant pharmacokinetic data is lacking.

objectivesTo evaluate the pharmacokinetics of clinically relevant dosing regimens of gabapentin in cats. ANIMALS: Eight research-purpose mixed-breed cats.

methodsCats were enrolled in a serial order, non-randomized pharmacokinetic study. Gabapentin was administered as an IV bolus (5 mg/kg), orally (10 mg/kg) as a single dose or twice daily for 2 weeks, or as a transdermal gel (10 mg/kg) in serial order. Serial blood samples were collected up to 48 hours. Plasma concentrations were determined using Ultra Performance Liquid Chromatography-Mass Spectrometry. Compartmental analysis was used to generate gabapentin time-concentration models.

resultsAfter IV administration CL (median (range)) and terminal half-life were 160.67 mL/kg*hr (119.63-199.11) and 3.78 hours (3.12-4.47), respectively. The oral terminal half-life was 3.63 hours (2.96-4.77), and 3.72 hours (3.12-4.51) for single and repeated dosing. T IMPORTANCE: Repeated oral dosing of gabapentin did not alter the drug's pharmacokinetics, making dose adjustments unnecessary with long-term treatment. As prepared, the transdermal route is an inappropriate choice for drug administration. These relevant data are important for future studies evaluating potential efficacy of the medication for treating chronic pain states in cats.

Indexed as

AnalgesicsAnimalsCatsFemaleGabapentinHalf-LifeInjections, IntravenousMaleAnalgesicsGabapentincompoundedfelinepaintransdermal

Identifiers

PMID30307652
PMCPMC6271300
OpenAlexW2896647745

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.